Join the club for FREE to access the whole archive and other member benefits.

Merger between regeneration companies AgeX and LyGenesis not going ahead


Key points from article :

Announced that they have discontinued negotiations for a merger agreement.

Directors determined that it was in the best interest of their respective shareholders not to proceed.

Cited the diversity of the companies’ technology platforms and product development focus.

AgeX Therapeutics will continue to consider new strategic opportunities as they arise - including licensing agreements for UniverCyte and PureStem.

LyGenesis will continue its allogeneic cell therapy for patients with end stage liver disease, and preclinical cell organ regeneration therapies.

Both companies to continue with the diverse technologies and product development

Mentioned in this article:

Tap on icon for description, click on resource name for more details.


Biotechnology company focused on the development of novel therapeutics for age-related degenerative disease


Organ regeneration using a patient's lymph nodes as bioreactors to grow ectopic organs